Healthcare industry

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

A rapid pyrogen test: the human immune system as model

Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

The Freiburg-based startup SpinDiag GmbH recently closed a 1.6 Mio. EUR seed-round with three private investors. The team developed a revolutionary point-of-care screening system for testing patients for antibiotic-resistant bacteria at their admission to hospitals and almost instantly so. The seed-capital will make it feasible to bring SpinDiag’s system from its current laboratory environment to first tests in hospitals.

Article - 18/05/2017

ImmuStick – novel rapid test for identifying disease pathogens

In some situations such as in the food and pharmaceutical industries or hospitals, a test to identify disease pathogens can be vital. At present, such tests are relatively time-consuming and can take hours or even days to produce results, depending on the pathogen. Scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are currently developing a rapid test called ImmuStick which is as easy to use…

Article - 30/05/2016

The unknown dark spot of the microcosm

The world of microorganisms is still largely unknown. Researchers such as Kai Sohn from the Fraunhofer IGB in Stuttgart are working on decoding, analysing and gradually gaining a better understanding of the microbial genome. In their search for new enzymes and other biomolecules, both biotechnologists and pharmacologists are interested in micoorganisms, and physicians are hoping that detailed insights into the microbial genome will lead to the…

Article - 14/04/2016

Rapid and unambiguous detection of infection in a miniature laboratory

In cooperation with industrial partners, researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have spent many years developing innovative diagnostic tools for use in infection biology. Among these are microsystems that combine complete test procedures on a “lab-on-a-chip” (LOC) and enable simultaneous analysis of several thousand parameters relatively quickly and with little effort. The scientists…

Article - 11/05/2015

How Lactobacillus bacteria fight Candida albicans infections

Fungal infections of skin and mucous membranes are relatively common. Around 75 percent of the human population lives with Candida albicans, a fungus that has no harmful effects in people with an intact immune system that can fight off systemic infections. However, in people with immune systems that have been weakened by antibiotics or radiotherapy for example C. albicans infections can lead to sepsis which may even be life-threatening. Prof. Dr.…

Article - 25/01/2014

Call for responsible antibiotics prescription

Heidelberg University Hospital and the University Medical Centre in Mannheim are working hard to counteract the increase of antibiotic resistance. Strategies include a European-wide system for infection surveillance, the training of health professionals in the responsible use of antibiotics and the search for novel antibiotic substances in unconventional organisms.

Article - 20/01/2014

Curetis AG: Miniaturised laboratory for the simple, rapid and reliable diagnosis of serious infections

Acute pneumonia usually leaves doctors with no choice the situation can quickly become life threatening requiring doctors to act quickly. Instead of waiting for laboratory results they often prescribe an antibiotic that is effective against numerous bacterial species in the hope that it will also work against the bacterium that has caused the inflammation in the lung tissue. Curetis AG from Holzgerlingen close to Stuttgart has developed a…

Article - 30/04/2012

Antibiotic resistance in hospitals

There is an alarming rise in infections caused by bacteria that are resistant to common antibiotics. A particular problem is nosocomial (hospital-acquired) infections of newborns, for which a Germany-wide surveillance system has been established. Novel natural substances with an antibiotic effect might be able to contain the danger.

Article - 29/08/2011

Ute Schepers – the therapeutic potential of small RNAs and molecular transporters

Small RNAs can specifically interfere with cellular mechanisms; or more precisely, with the cells’ protein biosynthesis machinery. Scientists have therefore decided to exploit this potential by using small RNAs against cancer cells or cells damaged in other ways. But the question arises as to how the small RNAs can reach the site where their role is to prevent the generation of dangerous proteins. Dr. Ute Schepers and her team from the Karlsruhe…

Human biobanks are treasure troves for medical research. Although the majority of these repositories were set up with public funds up until now they have only allowed external researchers limited access to information and samples. This will change from 22nd November 2010 when the first six German biobanks hold their inaugural meeting in Berlin to discuss and organise the establishment of the German Biobank Registry Project Portal.

Dr. Martin Burow, a proven expert in the field of prenatal diagnostics, has joined the LifeCodexx team as Head of Commercial Operations.

Press release - 04/11/2010

Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

Press release - 10/06/2009

University of Ulm to receive Draeger Prize for best publication in 2008

The Hospital of Anaesthesiology at Ulm University has been awarded the Draeger Prize by the European Society for Anaesthesiology for the best publication in the field of intensive care medicine in 2008. The university’s press office explained that the award-winning publication was a report on a two-year project investigating the effects of pure oxygen breathing to treat septic circulatory shock. The prize comes with a cheque of 10,000 euros.

Article - 14/05/2009

A multicentred approach for the treatment and prevention of diabetes

In order to counteract the increase in the number of diabetics it is necessary to take into account the entire psychosocial environment of the patients states Prof. Dr. Peter Nawroth a physician from Heidelberg University Hospital. The prevention of late complications must be a major goal of any treatment and patient consultation. By focusing on the development and investigation of the RAGE-dependent reaction system Nawroth and his team have…

Dossier - 24/04/2008

Contract manufacture: the order books remain full

The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.

Nele Wellinghausen has always been interested in plants and animals. As a teenager she studied ferns and won the German Jugend forscht competition. Nowadays the medical expert carries out research on microorganisms specifically on pathogens that lead to sepsis.